Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU



Rating:

Share or cite this content

Citations should be made in the following way:
S. Huang, X. Li, X. Guan (Guangzhou, China). Effects of ulinastatin in treatment of invasive candidiasis. Eur Respir J 2013; 42: Suppl. 57, 2441

Member's Comments

No comment yet.

Related content which might interest you: Effect of N-acetylcysteine on the activity of antibiotics against relevant respiratory pathogens Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Pulmonary actinomycosis: Successful treatment with oral antibiotics Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Outcomes of antioxidant administration in experimentally induced pneumonia Source: Annual Congress 2013 –The multiple faces of stress in lung injury Year: 2013 Anti-inflammatory treatment Source: International Congress 2017 – PG3 Bronchiectasis Year: 2017 Non-steroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia : A cohort study Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Safety of intravenous amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Atorvastatin as an anti inflammatory in bronchiectasis Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 Breakthrough invasive pulmonary aspergillosis (IPA) in patients receiving posaconazole prophylaxis (PPxis) Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 The efficacy of adjuvant use low molecular weight heparins in patients with community-acquired pneumonia Source: International Congress 2014 – Cells, biofilms and biomarkers in respiratory infections Year: 2014 Antimicrobial susceptibility of pseudomonasaeruginosa in CF patients before and after regular treatment with inhaled tobramycin Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Comparison of three modalities of corticosteroids administration in chronic rhinosinusitis Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Development of an antibody therapy for the treatment of pneumonia Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 N-acetylcysteine potentiates surfactant therapy for experimental meconium aspiration syndrome Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Investigation of gram positive antibiotics as aerosol administration (cubicin, vancomycin, zyvoxid) Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 A 12-week combination of clarithromycin and prednisone for the treatment of cryptogenic and radiation-induced organising pneumonia Source: International Congress 2015 – New insights into IIPs Year: 2015